Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Optalysys, Ltd. Raises $4 Million Seed Round to Break Bottlenecks in Genomic Research and Big Data Analysis | ||
By: Nasdaq / GlobeNewswire - 20 Sep 2017 | Back to overview list |
|
Light-Speed Optical Processing Startup to Democratize Access to High-Powered Computing and Drive Advances in Research and DevelopmentGLASSHOUGHTON, WEST YORKSHIRE, United Kingdom and RENO, Nev., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Optalysys Ltd . (@ Optalysys ), a start-up pioneering the development of light-speed optical coprocessors, today announced the company raised 3.95 million U.S. dollars / 3.05 million British pounds from undisclosed angel investors. Optalysys will use the funds to manufacture the first commercially available high-performance computing (HPC) processor based on its patented optical processing technology. "In many industries today, the demand for faster processing far exceeds the capabilities of conventional computing technology," said Dr. Nick New, CEO of Optalysys. "Until now, only large universities and organizations have had the means to use this kind of computing muscle. Our aim is to make supercomputing levels of processing power accessible to a much wider audience of scientists and researchers - which will promote more rapid advancement in such fields as precision medicine and machine learning, whilst addressing some of the fundamental limitations of conventional computing." Because its coprocessor excels at rapid and accurate pattern recognition (required for Big Data processing) and mathematical model generation applications, genomic sequence alignment is the first of many application areas targeted by Optalysys. On Aug. 31, Optalysys demonstrated the latest prototype for genomic searching at the Genome 10k/Genome Science conference held in Norwich, U.K. Optalysys partner, The Earlham Institute (EI), presented sequence alignment results that were produced using the Optalysys prototype. "Our prototype is on track to achieve game-changing improvements to process times over current methods whilst providing high levels of accuracy that are associated with the best software processes," said Emma Blaylock, director, chief commercial officer at Optalysys.
About OPTALYSYS
Press Contacts:
Margaret Pereira
Rachel Shatz
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Optalysys Ltd. via GlobeNewswire
HUG#2135486
|
||
|
||
Copyright 2017 Nasdaq / GlobeNewswire | Back to overview list |